Abstract: The present invention provides a unique combination of herbal ingredients designed to overcome natural inhibitors of human sexual response and allow for improved response and psychological effects. The composition is comprised of extracts taken from crataegus monogyna berry, turnera diffusa, pfaffia paniculata, ginkgo biloba, pygeum africanum, and ginsenosides extract, that are combined with L-arginine, L-glutamic acid and L-theanine in amounts effective to produce desired results.

Abstract: This invention relates to a nutritional intervention composition in a dry power form for enhancing satiety prior to a meal and extending satiety after a meal in a calorically efficient fashion. The dry nutritional composition includes protein, caseinmacropeptides (CMP) or glycomacropeptides (GMP) or any hydrolysis product of GMP, long chain fatty acids, soluble and/or insoluble fibers. The dry nutritional composition includes protein in the range of 0.21% to 88.30%, glycomacropeptide in the range of 0.05% to 87.72%, oleic acid in the range of 2.2% to 97.25%, soluble fibers in the range of 0.19% to 79.05%, and insoluble fibers in the range of 0.19% to 79.05%. The composition may also include plant to saponins, calcium and cholestyramine.

Abstract: One aspect of the present invention is a method for storing tissues and cells (typically erythrocytes) having the step of (1) stabilizing the cells with a reversible stabilizing agent. This method typically will have the additional steps of (2) loading the cells with a cryoprotectant, and typically (3) storing the cells in liquid, frozen, or dry state. This method will also typically have the additional step of (4) prior to use, reversing the stabilization reaction. Preferably, the erythrocytes are pre-treated with CO to complex the hemoglobin with CO. It is anticipated that a practical method according to the invention will include reoxygenation of the eryathrocytes, and also washing out reagents prior to in vivo use. Another aspect of the present invention is an erythrocyte that has had its shape stabilized by the reversible crosslinking of proteins in the erythrocyte, such as the structural proteins of the cytoskeleton.

Abstract: The invention relates to a process for the oxidation of substituted trimethylcyclohexenyl compounds in the presence of microorganisms of the order Actinomycetales and to the use of microorganisms in oxidation reactions.

Abstract: A nutritional composition for adding to food for enhancing and extending the satiety of the food by stimulating CCK levels in a calorically efficient manner and for reducing weight. The nutritional composition includes long chain fatty acids (C12 to C18) being in the range of 1.0 to 6.0 grams by weight of the composition; a calcium source being in the range of 1.0 to 4.0 grams by weight of the composition; potato fiber being in the range of 1.0 to 6.0 grams by weight of the composition; whey protein enriched with glycomacroprotein being in the range of 1.0 to 5.0 grams by weight of the composition; glucomannan fiber being in the range of 0.5 to 4.0 grams by weight of the composition; and alfalfa being in the range of 0.05 to 3.0 grams by weight of the composition. The food is selected from the group consisting of carbohydrates, proteins and fats.

Abstract: Estrogen-deficiency related cognitive dysfunction may be improved by administering a composition comprising an herbal composition to a woman. In a preferred embodiment the herbal composition comprises whole plant extract of Leucojum aestivum.

Abstract: The present invention provides antistress compositions containing various medicinal herbs which are composed of one or more medicinal herbs 2.0-40.0 g of fructus hordei germintus, messa medicata fermentata, fructus amomi and fructus crataegei; one or more medicinal herbs 2.0-40.0 g of radix polygalae, semen zizyphi spinosae and rhizoma acori graminei; one or more medicinal herbs 2.0-40.0 g selected from the group consisting of poria holen and poria, one or more medicinal herbs 2.0-40.0 g of folium phyllostachys, calus in taein phyllostachys, succus phyllostachys and radix scutellariae; one or more medicinal herbs 2.0-40.0 g of germinated Glycine max (L.) Merr, fructus amomicardamomi, semen glycine and semen lablab; one or more medicinal herbs 2.0-40.0 g of rhizoma zingiberis, radix asari, rhizoma zingiberis siccatum and radix aconiti; one or more medicinal herbs 2.0-40.0 g of bulbos allii fistulosi, herba ephedrae and folium perillae; and one or more medicinal herbs 2.0-40.

Abstract: The invention is based on the discovery that, for many drugs (e.g., antiviral or antimicrobial drugs such as antifungal or antibacterial drugs, including bacteriocidal or bacteriostatic drugs) and many pathogen strains (e.g., viral, fungal, or bacterial pathogens), a concentration of drug can be identified at which drug-resistant mutant pathogen strains are not selected. This concentration is herein referred to as the “mutant prevention concentration” (MPC). Maintaining serum concentrations of the drug above the MPC throughout a course of treatment should severely restrict selection of drug-resistant mutants. Additionally, it is discovered that drug-resistant mutant pathogens are selected exclusively within a drug concentration window, termed the “mutant selection window” (MSW). A quantitative expression of this window, which we call the “window index” (WI), is defined as the ratio of the MPC to the MIC.

Abstract: Cells and tissues, in particular sensitive cells and tissues, such as oocytes, fertilized oocytes and preimplantation embryos, which require highly stable physical and chemical environment for in vitro development, are cultured in closed containers submerged or immersed in thermostatically controlled liquid baths, the containers being provided with an appropriate inner atmosphere containing, e.g. carbondioxide, oxygen and humidity in appropriate levels. The incubator containers may e.g. be gas and liquid impervious, flexible, sealable, preferably transparent bags which after sealing are submerged or immersed directly in the thermostatically controlled liquid bath. The liquid in the bath is preferably water. An incubator for submerse or immerse culture of cells and tissues in the above manner is also described. Also a transportable liquid incubator for culturing cells and tissues in the field is described.

Abstract: A thermally stable enzyme composition contains an enzyme, and a heat stabilizer including a phospholipid and an oil-soluble vitamin. The enzyme composition can be prepared in the form of a powder by drying an enzyme solution containing a phospholipid and an oil-soluble vitamin to obtain an enzyme powder.

Abstract: A method is described for determining the effect of a drug or drugs on an attached culture of cells comprising (i) dissolving the phosphorescent compound, of known or predetermined quenching constant and lifetime at zero oxygen, in a culture medium at a selected temperature comprising an attached culture of test cells; (ii) introducing the drug(s), whose effect on the test cells is to be determined, into the culture medium; (iii) illuminating the culture medium with pulsed or modulated light at a level sufficient to cause the phosphorescent compound to emit measurable phosphorescence; (iv) measuring the emitted phosphorescence; and (v) calculating the phosphorescence lifetime and oxygen concentration gradient in the medium, thereby determining the effect of the drug on the respiration rate of the cells at the selected temperature. Apparatus for carrying out the method is also disclosed.

Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Abstract: An orally or topically administered composition capable of reducing inflammation in animals, preferably humans, suffering from inflammation, contains a therapeutically effective amount of a post-supercritical carbon dioxide alcoholic extract of ginger; therapeutically effective amounts of supercritical carbon dioxide extracts of rosemary, turmeric, oregano and ginger (preferably certified organic ginger); and therapeutically effective amounts of hydroalcoholic extracts of holy basil, turmeric, scutellariae baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and barberry. The composition is preferably orally administered on a daily basis for at least about 4 weeks.

Abstract: The present invention relates to a use of at least one protein fraction extracted from Hibiscus esculentus seeds and to a cosmetic composition containing such a fraction. Use of at least one soluble protein fraction extracted from Hibiscus esculentus seeds or okra as a substitute for casein in a cosmetic composition or product, the composition containing between 0.01% and 50.00% of the fraction.

Abstract: Methods for treating pain by intrathecal administration to a human patient of a therapeutically effective amount of a neurotoxin such as botulinum toxin type A are disclosed.

Abstract: The present invention relates to an enteric coated granule prepared by coating lactic acid bacteria-containing seed with a water-miscilble coating material and then, if desired, subjecting the first coated product to the second coating with a controlled-release coating material.

Abstract: Compositions for the treatment of fungal nail disease (onychomycosis), including camphor, menthol, eucalyptus and thymol are described. The ingredients are natural and very effective in treating the nail fungus.

Abstract: Improved preparations for the treatment of androgenetic alopecia comprise saw palmetto berry extract containing phytosterols and one or more low irritability constituents that enhance penetration of the extract into hair follicular pores. The low irritability penetration enhancer(s) may be selected from the group consisting of adapalene, tretinoin, retinaldehyde, tazarotene, salicylic acid, azelaic acid, and glycolic acid. Also provided is a method for reducing hair loss by application to the scalp of the improved preparations.

Abstract: One aspect of the present invention is a method for storing tissues and cells (typically erythrocytes) having the step of (1) stabilizing the cells with a reversible stabilizing agent. This method typically will have the additional steps of (2) loading the cells with a cryoprotectant, and typically (3) storing the cells in liquid, frozen, or dry state. This method will also typically have the additional step of (4) prior to use, reversing the stabilization reaction. Preferably, the erythrocytes are pre-treated with CO to complex the hemoglobin with CO. It is anticipated that a practical method according to the invention will include reoxygenation of the erythrocytes, and also washing out reagents prior to in vivo use. Another aspect of the present invention is an erythrocyte that has had its shape stabilized by the reversible crosslinking of proteins in the erythrocyte, such as the structural proteins of the cytoskeleton.

Abstract: The invention concerns an immunostimulatory and metastasis inhibiting fermented, dried vegetal material, pharmaceutical compositions containing the latter, the production process and the use of the dried material in the production dietary supplement and of immunostimulatory and metastasis inhibiting pharmaceutical compositions. The material according to the invention can be obtained by fermentation of wheat germ in an aqueous medium in the presence of Sacharomyces cerevisiae and by drying the fermented liquid.